Agilent, Seoul National University to Collaborate on New Research Center
News May 13, 2014
Agilent announced a collaboration with Seoul National University on a new research center that will support the College of Pharmacy's New Drug Development Center.
As stated in a memorandum of understanding signed by Seoul National University's College of Pharmacy and Agilent, the collaboration aims to conduct drug metabolism studies; research, evaluate and develop new compounds; understand the remedial effects and toxicity; assess pharmacokinetics; and conduct clinical tests for drugs.
"The College of Pharmacy at Seoul National University has a long tradition of driving innovation," said professor Bong-Jin Lee, dean of the college. "We have been leading Korea's pharmaceutical industry through the strategic use of technology and driving the development of new drugs. As we prepare students for the future, we will push the frontiers of drug development by expanding our research facilities, producing outstanding research, and leading the development of technology. We are pleased to collaborate with Agilent, as our scientists and researchers require the latest, most sophisticated instruments for their work."
Agilent will provide bio-analytical instruments and expertise in pharmaceutical drug testing and multi-omic biological systems to the College of Pharmacy. The jointly established research center will also serve as Agilent's reference site for drug development.
"One of the megatrends fueling life science research is the aging population," said Agilent's Rod Minett, general manager, Life Sciences, South Korea and South Asia-Pacific region. "Through continual research, trials and developments, we believe that newer, more effective drugs can be developed. As such, Agilent is pleased to support SNU College of Pharmacy's drive to create better drugs for a safer and healthier population."
This new research facility will be located at the New Drug Development Center at SNU's College of Pharmacy. The New Drug Development Center is an advanced multi-purpose research center for drug development, from identification of new drugs through to clinical trial testing. The six-story center houses facilities for analysis, efficacy testing, and medicinal ingredient research; it also contains a medicinal chemistry laboratory.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017